Speaker
Description
This study investigates a novel approach for selective targeting of tumor cells using the monoclonal antibody (mAb H10), produced via Plant Molecular Farming technology. mAb H10 specifically binds to the C domain of Tenascin-C (C-TNC), a tumor marker overexpressed in glioblastoma. The aim was to enhance antibody penetration into glioblastoma spheroids using electroporation, a technique that uses electric pulses to facilitate molecule delivery into cells.
The study developed a U87 glioblastoma spheroid model and tested two electroporation protocols: one with only long pulses (EP1) and another combining high- and low-voltage pulses (EP2). The results showed that EP1 was most effective, allowing deep penetration of mAb H10 into the spheroid without compromising its integrity. In contrast, EP2 caused spheroid disruption and debris formation, hindering visualization. Even without electroporation, mAb H10 partially penetrated the spheroid matrix, indicating its affinity for TNC.
These findings suggest that electroporation can enhance the delivery of mAb H10 into the tumor microenvironment, offering a promising strategy for targeted glioblastoma therapy. The study also highlights the potential of electroporation to optimize antibody delivery, and future work will focus on exploring additional protocols and evaluating the combination of mAb H10 with cytotoxic agents to improve treatment outcomes in solid tumors.
